VOR Vor Biopharma Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: VOR
  4. Earnings
?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 93
Relative Profitability: Rel. Profitability: 35

EPS in 2026 (TTM): $179.71

Last Report Period Date: Jun 30, 2026

Currently, VOR's 12-month EPS stands at $179.71, according to the most recent financial reports. During 2025, VOR reported a per-share earnings of -$70.5, which shows a decrease compared to the EPS of -$34.03 recorded in 2024. VOR recorded an EPS of -$1.16 for the quarterly period ending on Jun 30, 2026.

VOR earnings history

Historical annual and quarterly earnings per share (EPS) data for Vor Biopharma
EPS (TTM)
$179.71
EPS Growth YoY (Quarterly)
99.5%
EPS (Quarterly)
-$1.16
EPS Growth (Quarterly)
77.3%

In 2025, Vor Biopharma's earnings per share was -$70.5, a decrease of 107.2% from -$34.03 in 2024. Over the quarter ending Jun 30, 2026, the earnings per share came in at -$1.16, reflecting a 99.5% increase compared to the same quarter a year earlier. As of June 2026, the TTM EPS is $179.71. During 2024, the annual earnings per share was -$34.03, representing an increase of 2.8% compared to 2023.

VOR EPS vs price chart

VOR EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
99.5%
EPS growth YoY
-107.2%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Vor Biopharma has recorded a growth in earnings per share of 99.5% over the past 12 months (YoY, quarterly).

VOR Earnings Waterfall

Breakdown of revenue, profit and net income for Vor Biopharma

VOR Earnings vs Peers

What are the earnings of VOR compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
VOR Vor Biopharma Inc 0.11 -107.2% N/A N/A
ORMP Oramed Pharmaceuticals Inc 1.12 418.8% N/A N/A
OMER Omeros Corp 10.86 98.1% N/A N/A
OLMA Olema Pharmaceuticals Inc N/A 15% N/A N/A
VIVS VivoSim Labs Inc. N/A -214.7% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 19.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.